185 related articles for article (PubMed ID: 6215600)
1. [Medroxyprogesterone acetate (MAP) and aminoglutethimide (AG) in metastatic breast carcinoma. Preliminary report on a phase II study of the German Cancer Society's Internal Medicine Oncology Task Force].
Wander HE; Nagel GA; Blossey HC
Onkologie; 1982 Aug; 5 Suppl():28-33. PubMed ID: 6215600
[TBL] [Abstract][Full Text] [Related]
2. [Combined drug/hormone therapy in metastatic breast cancer with vincristine, adriamycin, cyclophosphamide and high dose medroxyprogesterone acetate--VAC-MAP. Preliminary results of a phase II study of the German Cancer Society's Internal Medicine Oncology Task Force].
Wander HE; Nagel GA; Blossey HC; Kordilla F; Stamm S; Matthressen W; Weiss J
Onkologie; 1982 Aug; 5 Suppl():8-12. PubMed ID: 6752794
[TBL] [Abstract][Full Text] [Related]
3. [Medroxyprogesterone acetate as glucocorticoid in combination with aminoglutethimide in the treatment of metastatic breast cancer].
Blossey HC; Wander HE; Nagel GA; Köbberling J; Kleeberg U
Onkologie; 1982 Aug; 5 Suppl():34-41. PubMed ID: 6290955
[TBL] [Abstract][Full Text] [Related]
4. Phase II study of aminoglutethimide and medroxyprogesterone acetate in the treatment of patients with advanced breast cancer.
Nagel GA; Wander HE; Blossey HC
Cancer Res; 1982 Aug; 42(8 Suppl):3442s-3444s. PubMed ID: 6123383
[TBL] [Abstract][Full Text] [Related]
5. Aminoglutethimide and medroxyprogesterone acetate in the treatment of patients with advanced breast cancer. A phase II study of the Association of Medical Oncology of the German Cancer Society (AIO).
Wander HE; Nagel GA; Blossey HC; Kleeberg U
Cancer; 1986 Nov; 58(9):1985-9. PubMed ID: 2944573
[TBL] [Abstract][Full Text] [Related]
6. Influence of aminoglutethimide on plasma levels of medroxyprogesterone acetate: its correlation with serum cortisol.
Van Deijk WA; Blijham GH; Mellink WA; Meulenberg PM
Cancer Treat Rep; 1985 Jan; 69(1):85-90. PubMed ID: 3155651
[TBL] [Abstract][Full Text] [Related]
7. [2d and 3d line hormonal therapy in postmenopausal metastatic breast tumor. Comparison of medroxyprogesterone acetate and aminoglutethimide in tamoxifen-resistant patients].
Garcia-Giralt E; Omodei Zorini C; Ferri L; Ayme Y; Carton M; Daban A; Delozier T; Fargeot P; Fumoleau P; Gorins A
Clin Ter; 1994 Aug; 145(8):113-21. PubMed ID: 7955956
[TBL] [Abstract][Full Text] [Related]
8. [Hormonal control of disseminated breast cancer].
Voznyĭ EK; Meshcheriakova NG; Biakhov MIu; Vasiuta NIu
Sov Med; 1990; (6):94-7. PubMed ID: 2144368
[No Abstract] [Full Text] [Related]
9. Clinical trial of combined hormone therapy (MAP + TAM) for metastatic breast cancer.
Pannuti F; Martoni A; Piana E; Tomasi L; Grieco A; Farris A; Saccani F; Baroni M
Chemioterapia; 1984 Aug; 3(4):211-5. PubMed ID: 6241846
[TBL] [Abstract][Full Text] [Related]
10. [Aminoglutethimide therapy in advanced breast cancer].
Kühböck J; Ludwig H; Pötzi P; Zielinski C
Wien Med Wochenschr; 1985 Dec; 135(23-24):608-11. PubMed ID: 4096007
[TBL] [Abstract][Full Text] [Related]
11. [Therapeutic effects of medroxyprogesterone acetate in recurrent or advanced breast cancer].
Yoshida M; Murai H; Miura S
Gan To Kagaku Ryoho; 1985 Mar; 12(3 Pt 1):516-23. PubMed ID: 3159345
[TBL] [Abstract][Full Text] [Related]
12. Oral route administration of medroxyprogesterone acetate (MAP) at high doses in the treatment of advanced breast cancer: clinical results.
Guarnieri A; Tucci E; D'Aniello C; Carli A; Mariani L; De Stefano A; Nardi P
Chemioterapia; 1984 Oct; 3(5):320-3. PubMed ID: 6241848
[TBL] [Abstract][Full Text] [Related]
13. [Combination therapy with medroxyprogesterone acetate and tegafur in tamoxifen- and adriamycin-resistant advanced breast cancers].
Wada T; Matunami N; Houjou T; Morikawa E; Mori N; Nakano K; Aizawa M; Kurooka K; Kadota K; Yamato M
Gan To Kagaku Ryoho; 1989 May; 16(5):2087-92. PubMed ID: 2525004
[TBL] [Abstract][Full Text] [Related]
14. [Preliminary results of treatment of hormone-dependent metastatic carcinoma of the breast with the bromocriptin-medroxyprogesterone acetate combination].
Mussa A; Dogliotti L; Di Carlo F
Minerva Med; 1977 Jun; 68(32):2233-44. PubMed ID: 577604
[TBL] [Abstract][Full Text] [Related]
15. [Value of hormone therapy in metastasizing breast cancer].
Samonigg H
Wien Med Wochenschr; 1985 Dec; 135(23-24):602-7. PubMed ID: 2937208
[TBL] [Abstract][Full Text] [Related]
16. [Aminoglutethimide plus high-dose medroxyprogesterone acetate versus aminoglutethimide plus cortisone in therapy of metastasizing breast cancer. An AIO phase III study].
Wander HE; Kleeberg UR; Essers U; Blossey HC; Nagel GA
Onkologie; 1987 Oct; 10(5):321-3. PubMed ID: 2960938
[No Abstract] [Full Text] [Related]
17. Treatment of metastatic breast cancer with aminoglutethimide after progression on chemotherapy and/or hormonal therapy with tamoxifen.
Brufman G; Biran S
Eur J Surg Oncol; 1985 Mar; 11(1):27-31. PubMed ID: 2985452
[TBL] [Abstract][Full Text] [Related]
18. Medroxyprogesterone acetate at very high doses in postmenopausal advanced breast cancer patients.
Pannuti F; Longhi A; Martoni A; Piana E; Baroni M
Chemioterapia; 1987 Dec; 6(6):396-8. PubMed ID: 2963702
[TBL] [Abstract][Full Text] [Related]
19. [High dose medroxyprogesterone acetate in metastatic breast cancer. Comparative clinical, pharmacokinetic and pharmacodynamic data of different forms of administration].
Blossey HC; Wander HE; Nagel GA; Köbberling J; Kleeberg U
Onkologie; 1982 Aug; 5 Suppl():13-6. PubMed ID: 6215599
[TBL] [Abstract][Full Text] [Related]
20. A possible new approach to the treatment of metastatic breast cancer: massive doses of medroxyprogesterone acetate.
Pannuti F; Martoni A; Lenaz GR; Piana E; Nanni P
Cancer Treat Rep; 1978 Apr; 62(4):499-504. PubMed ID: 350387
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
